– 94% reduction in HSV-2 shedding rate and 98% reduction in high viral load shedding rate, both statistically significant, observed in cohort evaluating 350 mg weekly oral dose compared to placebo ...

HealthDay News — Patients with herpes simplex virus type 2 (HSV-2) taking high doses of antiviral therapy to control the disease continue to experience short episodes of subclinical shedding or ...

The Nature Index 2024 Research Leaders — previously known as Annual Tables — reveal the leading institutions and countries/territories in the natural and health sciences, according to their output in ...

– Phase 1b studies for ABI-1179 and ABI-5366 running concurrently with interim data for both candidates on track for fall 2025 – SOUTH SAN FRANCISCO, Calif., June 30, 2025 (GLOBE NEWSWIRE) -- Assembly ...

Although it is known HSV-1 appears to cause less frequent genital symptoms than HSV-2, this was the first study to comprehensively examine oral and genital HSV-1 shedding using the highly sensitive ...

But the rate of shedding declines during the first year, researchers from the University of Washington (UW) School of Medicine in Seattle have found. "The findings suggest that the infection with ...

Herpes simplex virus is a master of bad timing—reappearing briefly, often unnoticed, and just long enough to keep the immune system on its toes. In its genital form, herpes simplex virus type 2 (HSV-2 ...

--Assembly Biosciences, Inc., a biotechnology company developing innovative therapeutics targeting serious viral diseases, today announced positive interim results from two Phase 1 b studies of its ...